The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs

Overview of attention for article published in Frontiers in Neurology, February 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

twitter: 10 X users

Citations

dimensions_citation: 43 Dimensions

Readers on

mendeley: 122 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 10 X posts from 10 X users, with an upper bound of 22,936 followers.

RT @PeterClausLab: SMN-enhancing drugs are a milestone for the treatment of SMA, but we should develop more: Our novel review about SMN-ind…

04 Feb 2020

Reply Repost Favourite

RT @PeterClausLab: SMN-enhancing drugs are a milestone for the treatment of SMA, but we should develop more: Our novel review about SMN-ind…

04 Feb 2020

Reply Repost Favourite

RT @PeterClausLab: SMN-enhancing drugs are a milestone for the treatment of SMA, but we should develop more: Our novel review about SMN-ind…

04 Feb 2020

Reply Repost Favourite

New Research: The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs: Spinal Muscular Atrophy (SMA) is monogenic motoneuron disease caused by low levels of the Survival of Motoneuron protein… https://t.co

03 Feb 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 6 additional X posts.